Global Human Recombinant Insulin 麻豆原创 Research Report 2024

Publication ID:

PB505256041

Publication Date:

May 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
The global Human Recombinant Insulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Recombinant Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Recombinant Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Recombinant Insulin include Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Recombinant Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Recombinant Insulin.
Report Scope
The Human Recombinant Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Litre) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Recombinant Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Recombinant Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech
Segment by Type
Rapid-Acting Human Insulin
Regular (Short Acting) Insulin
NPH (Intermediate Acting) Insulin
Long-Acting Human Insulin
Premixed Human Insulins Insulin
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Recombinant Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Recombinant Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Human Recombinant Insulin 麻豆原创 Overview
1.1 Product Overview and Scope of Human Recombinant Insulin
1.2 Human Recombinant Insulin Segment by Type
1.2.1 Global Human Recombinant Insulin 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Rapid-Acting Human Insulin
1.2.3 Regular (Short Acting) Insulin
1.2.4 NPH (Intermediate Acting) Insulin
1.2.5 Long-Acting Human Insulin
1.2.6 Premixed Human Insulins Insulin
1.3 Human Recombinant Insulin Segment by Application
1.3.1 Global Human Recombinant Insulin 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacies
1.3.5 Other
1.4 Global Human Recombinant Insulin 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Recombinant Insulin Revenue 2019-2030
1.4.2 Global Human Recombinant Insulin Sales 2019-2030
1.4.3 Global Human Recombinant Insulin 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Recombinant Insulin 麻豆原创 Competition by Manufacturers
2.1 Global Human Recombinant Insulin Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Human Recombinant Insulin Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Human Recombinant Insulin Average Price by Manufacturers (2019-2024)
2.4 Global Human Recombinant Insulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Recombinant Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Recombinant Insulin, Product Type & Application
2.7 Human Recombinant Insulin 麻豆原创 Competitive Situation and Trends
2.7.1 Human Recombinant Insulin 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Recombinant Insulin Players 麻豆原创 Share by Revenue
2.7.3 Global Human Recombinant Insulin 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Recombinant Insulin Retrospective 麻豆原创 Scenario by Region
3.1 Global Human Recombinant Insulin 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Recombinant Insulin Global Human Recombinant Insulin Sales by Region: 2019-2030
3.2.1 Global Human Recombinant Insulin Sales by Region: 2019-2024
3.2.2 Global Human Recombinant Insulin Sales by Region: 2025-2030
3.3 Global Human Recombinant Insulin Global Human Recombinant Insulin Revenue by Region: 2019-2030
3.3.1 Global Human Recombinant Insulin Revenue by Region: 2019-2024
3.3.2 Global Human Recombinant Insulin Revenue by Region: 2025-2030
3.4 North America Human Recombinant Insulin 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Recombinant Insulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Recombinant Insulin Sales by Country (2019-2030)
3.4.3 North America Human Recombinant Insulin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Recombinant Insulin 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Recombinant Insulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Recombinant Insulin Sales by Country (2019-2030)
3.5.3 Europe Human Recombinant Insulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Recombinant Insulin 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Human Recombinant Insulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Recombinant Insulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Recombinant Insulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Recombinant Insulin 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Recombinant Insulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Recombinant Insulin Sales by Country (2019-2030)
3.7.3 Latin America Human Recombinant Insulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Recombinant Insulin 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Recombinant Insulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Recombinant Insulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Recombinant Insulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Recombinant Insulin Sales by Type (2019-2030)
4.1.1 Global Human Recombinant Insulin Sales by Type (2019-2024)
4.1.2 Global Human Recombinant Insulin Sales by Type (2025-2030)
4.1.3 Global Human Recombinant Insulin Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Human Recombinant Insulin Revenue by Type (2019-2030)
4.2.1 Global Human Recombinant Insulin Revenue by Type (2019-2024)
4.2.2 Global Human Recombinant Insulin Revenue by Type (2025-2030)
4.2.3 Global Human Recombinant Insulin Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Human Recombinant Insulin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Recombinant Insulin Sales by Application (2019-2030)
5.1.1 Global Human Recombinant Insulin Sales by Application (2019-2024)
5.1.2 Global Human Recombinant Insulin Sales by Application (2025-2030)
5.1.3 Global Human Recombinant Insulin Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Human Recombinant Insulin Revenue by Application (2019-2030)
5.2.1 Global Human Recombinant Insulin Revenue by Application (2019-2024)
5.2.2 Global Human Recombinant Insulin Revenue by Application (2025-2030)
5.2.3 Global Human Recombinant Insulin Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Human Recombinant Insulin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Human Recombinant Insulin Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly and Company
6.2.1 Eli Lilly and Company Corporation Information
6.2.2 Eli Lilly and Company Description and Business Overview
6.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly and Company Human Recombinant Insulin Product Portfolio
6.2.5 Eli Lilly and Company Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Human Recombinant Insulin Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Julphar Gulf Pharmaceutical Industries
6.4.1 Julphar Gulf Pharmaceutical Industries Corporation Information
6.4.2 Julphar Gulf Pharmaceutical Industries Description and Business Overview
6.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolio
6.4.5 Julphar Gulf Pharmaceutical Industries Recent Developments/Updates
6.5 Bioton
6.5.1 Bioton Corporation Information
6.5.2 Bioton Description and Business Overview
6.5.3 Bioton Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bioton Human Recombinant Insulin Product Portfolio
6.5.5 Bioton Recent Developments/Updates
6.6 Gan & Lee Pharmaceuticals
6.6.1 Gan & Lee Pharmaceuticals Corporation Information
6.6.2 Gan & Lee Pharmaceuticals Description and Business Overview
6.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolio
6.6.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.7 Zhuhai United Laboratories
6.6.1 Zhuhai United Laboratories Corporation Information
6.6.2 Zhuhai United Laboratories Description and Business Overview
6.6.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zhuhai United Laboratories Human Recombinant Insulin Product Portfolio
6.7.5 Zhuhai United Laboratories Recent Developments/Updates
6.8 Biocon
6.8.1 Biocon Corporation Information
6.8.2 Biocon Description and Business Overview
6.8.3 Biocon Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Biocon Human Recombinant Insulin Product Portfolio
6.8.5 Biocon Recent Developments/Updates
6.9 Wanbang Biopharmaceuticals
6.9.1 Wanbang Biopharmaceuticals Corporation Information
6.9.2 Wanbang Biopharmaceuticals Description and Business Overview
6.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolio
6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates
6.10 Dongbao Enterprise Group
6.10.1 Dongbao Enterprise Group Corporation Information
6.10.2 Dongbao Enterprise Group Description and Business Overview
6.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Dongbao Enterprise Group Human Recombinant Insulin Product Portfolio
6.10.5 Dongbao Enterprise Group Recent Developments/Updates
6.11 PeproTech
6.11.1 PeproTech Corporation Information
6.11.2 PeproTech Human Recombinant Insulin Description and Business Overview
6.11.3 PeproTech Human Recombinant Insulin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 PeproTech Human Recombinant Insulin Product Portfolio
6.11.5 PeproTech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Recombinant Insulin Industry Chain Analysis
7.2 Human Recombinant Insulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Recombinant Insulin Production Mode & Process
7.4 Human Recombinant Insulin Sales and 麻豆原创ing
7.4.1 Human Recombinant Insulin Sales Channels
7.4.2 Human Recombinant Insulin Distributors
7.5 Human Recombinant Insulin Customers
8 Human Recombinant Insulin 麻豆原创 Dynamics
8.1 Human Recombinant Insulin Industry Trends
8.2 Human Recombinant Insulin 麻豆原创 Drivers
8.3 Human Recombinant Insulin 麻豆原创 Challenges
8.4 Human Recombinant Insulin 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.